PT96828B - Processo para a preparacao de um agente para a terapia de gangrena diabetica,contendo o factor xiii de coagulacao do sangue - Google Patents
Processo para a preparacao de um agente para a terapia de gangrena diabetica,contendo o factor xiii de coagulacao do sangue Download PDFInfo
- Publication number
- PT96828B PT96828B PT96828A PT9682891A PT96828B PT 96828 B PT96828 B PT 96828B PT 96828 A PT96828 A PT 96828A PT 9682891 A PT9682891 A PT 9682891A PT 96828 B PT96828 B PT 96828B
- Authority
- PT
- Portugal
- Prior art keywords
- factor xiii
- agent
- diabetic
- precipitate
- blood coagulation
- Prior art date
Links
- 108010071289 Factor XIII Proteins 0.000 title claims abstract description 35
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 title description 3
- 206010012665 Diabetic gangrene Diseases 0.000 claims abstract description 13
- 229940012444 factor xiii Drugs 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000011282 treatment Methods 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 102000005686 Serum Globulins Human genes 0.000 description 3
- 108010045362 Serum Globulins Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- -1 oral forms such as Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002643 kinesiotherapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2037284A JPH03240738A (ja) | 1990-02-20 | 1990-02-20 | 糖尿病性壊疽治療剤 |
| EP91102606A EP0499679B1 (en) | 1990-02-20 | 1991-02-22 | Therapeutic agent for diabetic gangrene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT96828A PT96828A (pt) | 1991-11-29 |
| PT96828B true PT96828B (pt) | 1998-07-31 |
Family
ID=40202967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96828A PT96828B (pt) | 1990-02-20 | 1991-02-20 | Processo para a preparacao de um agente para a terapia de gangrena diabetica,contendo o factor xiii de coagulacao do sangue |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3337488B2 (ja) * | 1992-03-06 | 2002-10-21 | アベンティス ファーマ株式会社 | 切迫流産治療剤 |
| DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| AU2003230321B8 (en) * | 2002-05-09 | 2009-07-30 | Medigenes | A pharmaceutical composition for treatment of wounds containing blood plasma or serum |
| JP6244079B2 (ja) * | 2008-04-21 | 2017-12-06 | ノボ ノルディスク ヘルス ケア アーゲー | 乾燥トランスグルタミナーゼ組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931399A (en) * | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
| US3904751A (en) * | 1970-12-22 | 1975-09-09 | Behringwerke Ag | Process for isolating a fibrin stabilizing factor from human placenta |
| JPS6029687B2 (ja) * | 1978-11-07 | 1985-07-12 | 株式会社ミドリ十字 | ヒト胎盤由来血液凝固第１０３因子の濃縮液の製造方法 |
| DE2916711A1 (de) * | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| JPS56135418A (en) * | 1980-03-27 | 1981-10-22 | Green Cross Corp:The | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human |
| DE3419581A1 (de) * | 1984-05-25 | 1985-11-28 | Behringwerke Ag, 3550 Marburg | Verfahren zur gewinnung einer faktor xiii-praeparation sowie ihre verwendung |
| JPS63196520A (ja) * | 1987-02-09 | 1988-08-15 | Hoechst Japan Kk | 潰瘍性大腸炎治療剤 |
| US4904751A (en) * | 1987-12-21 | 1990-02-27 | Texaco Chemical Company | N,N'-dialkyl substituted polyoxyalklene amines as curing agents for blocked isocyanates |
| AT397203B (de) * | 1988-05-31 | 1994-02-25 | Immuno Ag | Gewebeklebstoff |
| DE3829524A1 (de) * | 1988-08-31 | 1990-03-01 | Behringwerke Ag | Verwendung von transglutaminasen als immunsuppressiva |
-
1990
- 1990-02-20 JP JP2037284A patent/JPH03240738A/ja active Granted
-
1991
- 1991-02-15 US US07/656,472 patent/US5164373A/en not_active Expired - Lifetime
- 1991-02-18 KR KR1019910002557A patent/KR0184008B1/ko not_active Expired - Fee Related
- 1991-02-19 AU AU71178/91A patent/AU647078B2/en not_active Expired
- 1991-02-19 CA CA002036592A patent/CA2036592C/en not_active Expired - Lifetime
- 1991-02-19 IE IE56591A patent/IE69393B1/en not_active IP Right Cessation
- 1991-02-20 PT PT96828A patent/PT96828B/pt not_active IP Right Cessation
- 1991-02-22 DE DE69113437T patent/DE69113437T2/de not_active Expired - Lifetime
- 1991-02-22 EP EP91102606A patent/EP0499679B1/en not_active Expired - Lifetime
- 1991-02-22 AT AT91102606T patent/ATE128358T1/de not_active IP Right Cessation
- 1991-02-22 DK DK91102606.0T patent/DK0499679T3/da active
- 1991-02-22 ES ES91102606T patent/ES2077698T3/es not_active Expired - Lifetime
-
1995
- 1995-10-06 GR GR950402776T patent/GR3017672T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU647078B2 (en) | 1994-03-17 |
| KR0184008B1 (ko) | 1999-05-01 |
| ATE128358T1 (de) | 1995-10-15 |
| DE69113437D1 (de) | 1995-11-02 |
| CA2036592C (en) | 2004-04-06 |
| ES2077698T3 (es) | 1995-12-01 |
| IE69393B1 (en) | 1996-09-18 |
| EP0499679A1 (en) | 1992-08-26 |
| CA2036592A1 (en) | 1991-08-21 |
| EP0499679B1 (en) | 1995-09-27 |
| AU7117891A (en) | 1991-08-22 |
| GR3017672T3 (en) | 1996-01-31 |
| KR910021244A (ko) | 1991-12-20 |
| DE69113437T2 (de) | 1996-04-11 |
| DK0499679T3 (da) | 1996-02-05 |
| JPH03240738A (ja) | 1991-10-28 |
| US5164373A (en) | 1992-11-17 |
| PT96828A (pt) | 1991-11-29 |
| IE910565A1 (en) | 1991-08-28 |
| JPH0561253B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT392905B (de) | Verfahren zur behandlung eines blutgerinnungsfaktors viii-konzentrats | |
| DE3400413C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
| PT87150B (pt) | Processo para a preparacao de materiais injectaveis apropriados para aumentar o tecido mole a partir da placenta | |
| DE69120192T2 (de) | Verfahren zur Herstellung von sekretorischen Immunoglobulin-A-Präparaten | |
| DE3061547D1 (en) | Process of preparation of an intravenous immunoglobulin solution, containing concentrated igm | |
| JPS59133276A (ja) | 結合コラ−ゲン繊維シ−トの製造方法 | |
| Schwartzman | Hyaluronidase: A review of its therapeutic use in pediatrics | |
| US3916026A (en) | Method for the preparation of gamma-globulin suitable for intravenous use | |
| KR0137476B1 (ko) | 조산아의뇌실내출혈방지용치료제 | |
| EP0106608A2 (en) | Method of lyophilizing cold insoluble globulin | |
| KR960007922B1 (ko) | 조직단백질 pp4의 저온살균법 | |
| KR100255095B1 (ko) | 유산 위험 치료제 | |
| PT96828B (pt) | Processo para a preparacao de um agente para a terapia de gangrena diabetica,contendo o factor xiii de coagulacao do sangue | |
| KR20000035446A (ko) | 세포접착분자 발현억제제 | |
| DE2734150A1 (de) | Verfahren zur gewinnung von human- lysozym | |
| JPH07206888A (ja) | 胎盤抽出物およびその製造方法 | |
| NO143478B (no) | Fremgangsmaate ved fremstilling av gamma-globuliner | |
| DE68913212T2 (de) | Ein reines faktor i-protein und verfahren zur herstellung. | |
| JPS5840532B2 (ja) | Ｉｇａ オヨビ ｉｇｍ ノネツアンテイカホウ | |
| Cullumbine | Leukotaxine and histamine | |
| Neuhaus et al. | Hepatic production of serum alpha2 and beta globulins in rats after injury | |
| US2704737A (en) | Urea-modified insulin and process for preparing | |
| US3919186A (en) | Method of recovering cytobiotic globulin from skin tissue | |
| JPS58121220A (ja) | 寒冷不溶性グロブリンの製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19910725 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19980413 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20121015 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20130415 |